Clinical Trials in Orléans, France
1 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 4
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
GFPC Investigation500 enrolled41 locationsNCT06646471
Recruiting
Not Applicable
Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Metastatic Triple-Negative Breast Carcinoma
UNICANCER472 enrolled51 locationsNCT06505018
Recruiting
Not Applicable
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie100 enrolled46 locationsNCT05122806
Recruiting
Phase 2
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
NSCLC
Groupe Francais De Pneumo-Cancerologie45 enrolled27 locationsNCT06620835
Recruiting
Phase 3
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
Metastatic Non-squamous Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris1,166 enrolled37 locationsNCT05692999
Recruiting
Phase 2Phase 3
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
Metastatic NSCLC
Intergroupe Francophone de Cancerologie Thoracique1,360 enrolled44 locationsNCT05255302
Recruiting
Not Applicable
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Intergroupe Francophone de Cancerologie Thoracique300 enrolled36 locationsNCT06053099